SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001739410-24-000012
Filing Date
2024-02-06
Accepted
2024-02-06 08:15:06
Documents
15
Period of Report
2024-02-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlyb-20240206.htm   iXBRL 8-K 30951
2 EX-99.1 rlyb-202462xex991.htm EX-99.1 23745
  Complete submission text file 0001739410-24-000012.txt   195916

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rlyb-20240206.xsd EX-101.SCH 1892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rlyb-20240206_lab.xml EX-101.LAB 25850
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rlyb-20240206_pre.xml EX-101.PRE 13575
16 EXTRACTED XBRL INSTANCE DOCUMENT rlyb-20240206_htm.xml XML 2917
Mailing Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510
Business Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510 203- 859-3820
Rallybio Corp (Filer) CIK: 0001739410 (see all company filings)

IRS No.: 851083789 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40693 | Film No.: 24598151
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)